Citations

Mayo Clinic

Clear

188 citation(s) found for "Wu, Connie".

Macrophages stimulate mammary stem cells
Eaves, Connie J. , Kannan, Nagarajan

Science | June 28, 2018 | Volume: 360 | Issue: 6396 | Pages: 1401-1402

10.1126/science.aau1394 | PMID 29954968 Get It

Macrophages help mediate hormone-controlled changes in the mouse mammary gland
207Clinical utility of performing magnetic resonance imaging in patients with cardiac implantable electronic devices in situ
Padmanabhan, Deepak , Tandon, Navdeep, Mulpuru, Siva K. , Mehta, Ramila A. , Dalzell, Connie, Olson, Nora E., Felmlee, Joel P. , Jondal, Mary Lou, Watson, Robert E. , Cha, YONG-M, Friedman, Paul A. , Kella, Danesh , Deshmukh, Amrish , Kapa, Suraj , Asirvatham, Samuel J.

EP Europace | March 19, 2018 | Volume: 20 | Issue: suppl_1 | Pages: i22-i23

10.1093/europace/euy015.056 Get It

Mortality After Magnetic Resonance Imaging of the Brain in Patients With Cardiovascular Implantable Devices
Padmanabhan, Deepak , Jondal, Mary Lou, Hodge, David O. , Mehta, Ramila A. , Acker, Nancy G., Dalzell, Connie, Asirvatham, Samuel J. , Cha, Yong‐Mei , Felmlee, Joel P. , Watson, Robert E. , Friedman, Paul A. , Jondal, Mary L, Dalzell, Connie M, Kapa, Suraj , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | January 10, 2018 | Volume: 11 | Issue: 1 | Pages: No page available

10.1161/circep.117.005480 | PMID 29321191 Get It

Background: Use of magnetic resonance imaging (MRI) brain is restricted in patients with cardiovascular implantable electronic devices (CIEDs). We proposed to determine whether mortality difference exists for patients with non–MRI-conditional CIEDs undergoing brain MRI compared with controls. Methods and Results: Retrospective analysis of prospectively collected data was performed to compare all-cause mortality in patients with CIEDs undergoing brain MRI (CIED-MRI) with 3 control groups matched for age, sex, imaging year, and type of CIED: (1) no CIED, brain MRI (no–CIED-MRI); (2) CIED, brain computerized tomography (CT) scan (CIED-CT); and (3) no CIED, brain CT (no–CIED-CT). The primary outcome was a significant difference ( P <0.05) between estimated mortality rates. Secondary outcomes were changes in device function before and after brain MRI. The estimated all-cause mortality at 5 years for the CIED-MRI group [mean age (±SD), 68.2 years (15.3 years); 61.2% men] was not significantly different from patients who underwent CT with or without a device (CIED-CT group: hazard ratio, 0.814; 95% confidence interval, 0.593–1.117; P =0.2; no–CIED-CT group: hazard ratio, 1.149; 95% confidence interval, 0.818–1.613; P =0.4). There was a significant increase in mortality between CIED-MRI and no–CIED-MRI groups (hazard ratio, 1.463; 95% confidence interval, 1.019–2.099; P =0.04). Conclusions: Brain MRI in patients with CIEDs does not carry an increased mortality risk compared with brain CT and can be performed with adherence to appropriate procedural protocols.
Gene Expression Profiling and Assessment of Vitamin D and Serotonin Pathway Variations in Patients With Irritable Bowel Syndrome
Dussik, Christopher M. , Hockley, Maryam, Grozić, Aleksandra, Kaneko, Ichiro , Zhang, Lin , Sabir, Marya S. , Nickerson, Cheryl A. , Yale, Steven H. , Rall, Christopher, Foxx–Orenstein, Amy E., Borror, Connie M., Sandrin, Todd R. , Foxx-Orenstein, Amy E, Park, Jin Kee , Wang, Jie , Jurutka, Peter W.

Journal of Neurogastroenterology and Motility | January 2, 2018 | Volume: 24 | Issue: 1 | Pages: 96-106

10.5056/jnm17021 | PMID 29291611 Get It

Abstract 4258: Influence of lifestyle factors on adipocyte size in human breast tissue
Campbell, Kristin L. , Neil‐Sztramko, Sarah , Zhu, David A. H., Sayyari, Sarah, Bland, K I, Kannan, Nagarajan , Eaves, Connie J. , Little, Jonathan P. , Csizmadi, Ilona , Bland, Kelcey A. , Johnson, James D. , Neil-Sztramko, Sarah

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 4258-4258

10.1158/1538-7445.am2017-4258 Get It

Abstract Background: Accumulating epidemiological studies positively associate healthy body mass index (BMI) and higher physical activity with lowered risk of postmenopausal breast cancer. Many of the proposed biomarkers underlying these associations, such as insulin, inflammatory markers, steroid hormones, and adipokines, are produced or regulated by adipose tissue. However, the biological impact of lifestyle factors at the level of the breast tissue, particularly adipose tissue in the breast, is unclear and may play a role in the etiology of breast cancer. Methods: Using a cross-sectional design, we examined the impact of demographic and lifestyle factors on histological features of breast adipose tissue. Women (age) undergoing reduction mammoplasty surgery were consented to collection of their cancer-free breast tissue at the time of surgery. An adipose rich section of the sample was dissected under sterile conditions and formalin fixed. Samples were sectioned at 7 µm thickness and stained with hematoxylin and eosin. The stained sections were imaged and mean adipocyte size was determined as diameter (µm) from 3 randomly selected areas at 10X magnification and each sample was scored by two independent assessors using Image J software. BMI status documented at the time of surgery was abstracted form medical records. A subset of women completed an additional visit where percent total body fat was measured by air displacement plethysmography and aerobic fitness (VO2peak) was measured by a maximal graded exercise test with expired gas collection. The association between adipocyte size and demographic/lifestyle factors was examined using multivariate linear regression adjusted for age and menopausal status. Results: Participants (n=42) were primarily Caucasian (77%) and pre/peri-menopausal (62%), with a mean age of 44.6±12.9 years (range 19-70) and mean BMI of 27.7±5.1 kg/m2 (range 19.1-37.4). Adipocyte size was associated with BMI (per 5 kg/m2 increase, β = 5.6±2.15, p=0.01) and number of pregnancies (β = 6.04±2.34, p=0.02), but not age (β = 0.1±0.3, p=0.81). In the subset of participants who completed an additional study visit (n=9), there was a trend towards an inverse association between adipocyte size and aerobic fitness (per 2 ml/kg/min of O2 consumption, β = -3.54±1.52, p=0.07) and percent body fat (per 2% increase, β = 1.94±1.28, p=0.17) in unadjusted analyses. Conclusion: Higher BMI is associated with larger adipocyte size in adipose tissue taken from the breast, suggesting a biological role for body composition in influencing gross histological features of adipocytes and its behavior that would impact the health of the mammary gland. A better understanding of the biological mechanisms underlying the observed epidemiological associations are needed to guide the development of intervention strategies and the most effective public health messages for breast cancer prevention. Citation Format: Kristin L. Campbell, Nagarajan Kannan, Sarah E. Neil-Sztramko, Connie J. Eaves, Jonathan P. Little, Ilona Csizmadi, David Zhu, Sarah Sayyari, Kelcey Bland, James D. Johnson. Influence of lifestyle factors on adipocyte size in human breast tissue [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4258. doi:10.1158/1538-7445.AM2017-4258
Abstract 3459: BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells
He, Zhengcheng , Nemirovsky, Oksana, Maxwell, Christopher A. , Kannan, Nagarajan , Eaves, Connie J.

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 3459-3459

10.1158/1538-7445.am2017-3459 Get It

Abstract BRCA1 deficiency alters the relative proportions of progenitor cells in preneoplastic mammary tissue, and typically associates with breast cancers characterized by genomic instability and a basal-like cell phenotype. Oriented division of progenitor cells is one mechanism these cells use to maintain tissue homeostasis, and to suppress tumor formation. We now show that shRNA-mediated reduction of BRCA1 levels in non-tumorigenic and immortalized or freshly isolated, normal human mammary cells alters their plane of division with graded consequences that include the induction of aneuploidy in progeny cells, perturbation of polarity in spheroid cultures, and inhibition of clonal growth with favored expression of basal features. We also demonstrate a requirement for BRCA1 in establishing cortical asymmetry of NUMA-dynein complexes. Mutation of a single BRCA1 allele (BRCA1 185delAG/+) altered the division axis of isolated cells but their deficient spindle positioning was supervised by CDH1-positive adherens, which sustained oriented divisions and produced colonies with luminal features. These findings reveal a previously unrecognized consequence of mutant BRCA1 on the cell division axis, post-mitotic integrity and phenotype control in normal human mammary epithelial cells. Note: This abstract was not presented at the meeting. Citation Format: Zhengcheng He, Oksana Nemirovsky, Nagarajan Kannan, Connie Eaves, Christopher A. Maxwell. BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3459. doi:10.1158/1538-7445.AM2017-3459
A Consensus Set of Outcomes for Parkinson’s Disease from the International Consortium for Health Outcomes Measurement
Roos, Paul de , Bloem, Bastiaan R. , Kelley, Thomas A., Antonini, Angelo , Dodel, Richard , Hagell, Peter , Mehta, Shyamal H. , Odin, Per , Chaudhuri, К. Ray , Wilson, Bil, Uitti, Ryan J. , Marras, Connie , Martínez‐Martín, Pablo , Weintraub, Daniel , Wilson, Bil, Antonini, Angelo

Journal of Parkinson's Disease | June 30, 2017 | Volume: 7 | Issue: 3 | Pages: 533-543

10.3233/jpd-161055 | PMID 28671140 Get It

Mild cognitive impairment as a risk factor for Parkinson's disease dementia
Hoogland, Jeroen , Boel, Judith A., Bie, Rob M.A. de , Geskus, Ronald B. , Schmand, Ben , Dalrymple‐Alford, John C. , Goldman, Jennifer G. , Tröster, Alexander I. , Burn, David J. , Geurtsen, Gert J. , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Rodríguez‐Oroz, María , Goldman, Jennifer G , Marras, Connie , Adler, Charles H. , Litvan, Irene , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Dalrymple-Alford, John C , de Bie, Rob M A , Geurtsen, Gert J

Movement Disorders | June 12, 2017 | Volume: 32 | Issue: 7 | Pages: 1056-1065

10.1002/mds.27002 | PMID 28605056 Get It

ABSTRACT Background The International Parkinson and Movement Disorder Society criteria for mild cognitive impairment in PD were recently formulated. Objectives The aim of this international study was to evaluate the predictive validity of the comprehensive (level II) version of these criteria by assessment of their contribution to the hazard of PD dementia. Methods Individual patient data were selected from four separate studies on cognition in PD that provided information on demographics, motor examination, depression, neuropsychological examination suitable for application of level II criteria, and longitudinal follow‐up for conversion to dementia. Survival analysis evaluated the predictive value of level II criteria for cognitive decline toward dementia as expressed by the relative hazard of dementia. Results A total of 467 patients were included. The analyses showed a clear contribution of impairment according to level II mild cognitive impairment criteria, age, and severity of PD motor symptoms to the hazard of dementia. There was a trend of increasing hazard of dementia with declining neuropsychological performance. Conclusions This is the first large international study evaluating the predictive validity of level II mild cognitive impairment criteria for PD. The results showed a clear and unique contribution of classification according to level II criteria to the hazard of PD dementia. This finding supports their predictive validity and shows that they contribute important new information on the hazard of dementia, beyond known demographic and PD‐specific factors of influence. © 2017 International Parkinson and Movement Disorder Society
CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
Nayak, Lakshmi , Ferreri, Andrés J.M. , Batlevi, Connie Lee , Batchelor, Tracy T. , Rubenstein, James L. , Johnston, Patrick B. , Ramchandren, Radhakrishnan , Soussain, Carole , Becker, Kevin, Illerhaus, Gerald , Herrera, Alex F. , Masood, Aisha, IWAMOTO, FABIO MASSAITI , Santoro, Armando , Singer, Samuel , Drappatz, Jan , Witzens‐Harig, Mathias , Shipp, Margaret Ann

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 420-421

10.1002/hon.2440_2 Get It

Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study
Larsen, Jeremy T. , Leis, José F., LaPlant, Betsy, Call, Tim G., Pettinger, Adam, Hanson, Curtis A. , Erlichman, Charles , Reeder, Craig B. , Nikcevich, Daniel A., Bowen, Deborah A., Conte, Michael, Boysen, Justin C. , Secreto, Charla, Lesnick, Connie , Tschumper, Renee C. , Jelinek, Diane F., Call, Tim, Hanson, Curtis, Habermann, Thomas Matthew, Reeder, Craig, Bowen, Deborah, Boysen, Justin, Tschumper, Renee, Jelinek, Diane, Ding, Wei , Shanafelt, Tait D. , Call, Timothy G., Habermann, Thomas M. , Kay, Neil E. , Ding, Wei

American Journal of Hematology | April 12, 2017 | Volume: 92 | Issue: 8 | Pages: 759-763

10.1002/ajh.24762 | PMID 28402581 Get It

Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK‐2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard phase I design was used with cohorts of three plus three patients to determine the maximum tolerated dose (MTD) of MK‐2206 in combination with BR in relapsed CLL. Single‐agent MK‐2206 (weekly dosed) was administered one‐week in advance before BR on cycle 1 and subsequently was given with BR at the same time for cycle 2‐6. Phase II employed the MTD of MK‐2206 with BR to evaluate safety and efficacy of this study combination. Thirteen relapsed/refractory CLL were treated for maximal 6‐cycle of therapy. The maximum tolerated dose of MK‐2206 was 90 mg by mouth once weekly. The most common grade 3/4 adverse events were neutropenia (46%), febrile neutropenia (23%), rash (15%), diarrhea (15%), and thrombocytopenia (15%). Overall response rate was 92% with a median progression free survival and treatment free survival of 16 and 24 months, respectively. Five patients (38%) achieved complete remission or complete remission with incomplete count recovery, two of whom were MRD negative. The efficacy and tolerability of this combination indicates that Akt inhibition combined with chemoimmunotherapy is a promising novel treatment combination in CLL and deserves further prospective clinical trial.